Melanotan II: a pan-melanocortin agonist with a clinical cousin

Melanotan II is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Seven residues, a lactam between aspartic acid and lysine, an acetyl at the amino terminus, an amide at the carboxyl terminus, norleucine in place of methionine, D-phenylalanine in place of the natural L-phenylalanine of α-MSH. Victor Hruby and Mac Hadley made that ring at the University of Arizona in a photoprotection programme: occupy the pigment receptor, write eumelanin, spare the ultraviolet. The ring didn't stay on one receptor. It is a super-agonist at MC1R, MC3R, MC4R and MC5R, the four melanocortin G-protein-coupled receptors that share the His-Phe-Arg-Trp pocket, and it is a poor ligand at MC2R, the ACTH receptor on the adrenal. All four of the receptors it does occupy couple primarily to Gs, so occupancy raises cyclic AMP. What the cell writes with that rise depends on which receptor you occupied and where it lives. Pigment is only the first invoice. Appetite, flushing, sebum and arousal come along because the pocket is shared and the tissues are not. That's the whole point of a pan-agonist, and it's why this page exists at the length it does.

In short. Melanotan II is a small cyclic peptide from an Arizona lab. It turns on four related receptors at once, not only the one that makes dark pigment.

The endogenous parent is α-melanocyte-stimulating hormone, thirteen residues, acetylated and amidated, sequence Ac-SYSMEHFRWGKPV-NH2. It is cut from pro-opiomelanocortin, POMC, a polyprotein written in corticotrophs, melanotrophs and a thin population of hypothalamic neurons. Convertases decide which hormone you get. In a corticotroph the principal product is ACTH, thirty-nine residues, the ligand that tells the adrenal cortex to make cortisol. In a melanotroph, and in those hypothalamic cells, the same precursor is cut further to α-MSH. The core pharmacophore is His-Phe-Arg-Trp, residues six to nine, the tetrapeptide the five melanocortin receptors actually want in the pocket. The last three letters are lysine-proline-valine, KPV, the anti-inflammatory tail. Medicinal chemistry on this family has two directions. Melanotan II is addition and cyclisation: pin the core, resist proteases, occupy almost the whole sheet. KPV is subtraction: keep the tail, lose most of the pigment and most of the appetite agonism. This page is the pan-agonist. The fragment has its own.

In short. The natural hormone is thirteen amino acids long. Melanotan II keeps the middle that fits the receptors and pins it in a ring so enzymes cannot eat it quickly.

A pan-agonist is a tool for a specific question. If you want to know whether a phenotype is melanocortin-gated at all — pigment in a melanocyte, cyclic AMP in an MC4R-expressing neuron, feeding in a rodent — the unselective ligand is how you ask. If you then want to know which subtype did the work, you change the molecule, or you use a knockout, or you use an antagonist, or you pick the licensed cousin that was taken through to a label on one job. Afamelanotide occupies MC1R for photoprotection in erythropoietic protoporphyria. Bremelanotide occupies MC3R and MC4R for a defined hypoactive-sexual-desire indication. Setmelanotide occupies MC4R for rare genetic obesity on the POMC pathway. Three peptides, three jobs, three labels. Melanotan II is none of those three medicines. It is the unselective parent those programmes learned from. Treating the research ring as a sunbed, or as Vyleesi in a different bottle, mixes a probe with a product. What follows is the chemistry, the five receptors, the Arizona extras, and the distance between a chromatogram and a licence.

In short. A pan-agonist asks whether the whole family is involved. Licensed drugs from the same family each picked one job. This ring is the research parent, not those medicines.

The linear analogue that came first is [Nle4, D-Phe7]α-MSH. Methionine at position four of α-MSH oxidises; norleucine does not, and the side chain is close enough that the receptor still accepts it. Phenylalanine at position seven, in the HFRW core, was flipped to the D-amino acid so proteases would hesitate and potency would rise. That molecule is Melanotan I, later afamelanotide, later Scenesse. It stayed closer to the thirteen-residue parent. Melanotan II is the next move: cut to a heptapeptide, keep norleucine and D-phenylalanine, and close a lactam bridge between aspartic acid and lysine so the HFRW tetrapeptide is held in a turn the pocket likes. Super-agonist is the word the Arizona papers used, and they meant potency at four receptors that made the linear parent look polite. Enzymatic resistance is the other point of the D-amino acid and the cycle. A linear α-MSH in plasma is a short conversation. The cyclic lactam is a longer one. Hruby's chemistry and Hadley's physiology were a collaboration of the sort that still looks good on a paper: a named sequence, a named cyclisation, a named receptor sheet, a named set of rodent pigment and behaviour assays.

In short. Chemists swapped two amino acids so the chain would last, then closed a ring around the bit the receptors want. That ring is Melanotan II.

A lactam is an amide that closes a ring rather than extending a chain. Aspartic acid contributes the carboxyl; lysine contributes the side-chain amine; the bond between them pins residues two to seven of the analogue into a cycle. The His-D-Phe-Arg-Trp core sits on that cycle in a conformation the melanocortin receptors bind with high affinity. Linear peptides of this length have many rotatable bonds; the cycle throws most of those degrees of freedom away, which is why cyclisation is a classic potency trick and not a cosmetic. The same trick is a protease trick. Exopeptidases that nibble from the ends still meet an acetyl and an amide. Endopeptidases that want an extended strand meet a turn they cut poorly. Molecular weight is about 1024 daltons. CAS 121062-08-6. Identity is that sequence plus the lactam plus the D-phenylalanine. A linear deletion peptide will not copy the mass or the pharmacology. A missed coupling in solid-phase synthesis makes an N-minus-one contaminant that looks almost right on a cheap ultraviolet scan. That's why a certificate that names sequence, mass and purity is the invoice a research ligand owes you.

In short. The ring is a chemical bridge between two amino acids. It holds the shape the receptors like and slows the enzymes that would otherwise cut the chain.

Pan, in this family, has a precise meaning. Binding and functional assays in the 1990s and after put Melanotan II at MC1R, MC3R, MC4R and MC5R with nanomolar or sub-nanomolar potency, Gs-coupled cyclic AMP as the default readout, and negligible activity at MC2R. MC2R wants ACTH and needs the accessory protein MRAP to traffic and to signal; the cyclic heptapeptide is a poor ligand there, which is why a tanning probe doesn't routinely present as an ACTH analogue. That selectivity is luck as much as design, and it's worth keeping on the page so nobody files 'melanocortin agonist' under steroidogenesis. The four receptors it does occupy share the HFRW pocket and do not share tissue. MC1R lives on melanocytes, and also on macrophages and keratinocytes. MC3R and MC4R live in hypothalamus and elsewhere in the brain. MC5R lives on exocrine glands, sebaceous epithelium in particular. One ancestral key. Four locks. The phenotype is the lock's address, not a mystic property of the peptide. A pan-agonist occupies the locks it can reach. The extras in a volunteer study are those locks doing their jobs.

In short. Melanotan II is strong at four of the five related receptors and weak at the adrenal one. The effects you see depend on which tissues those four receptors sit in.

Hadley's physiology was pigment first, because that was the grant. Rodent coat colour, melanocyte tyrosinase, a melanin pellet you can see: those are fair assays for an MC1R agonist. The clinic then read the rest of the sheet because a cyclic analogue that occupies MC3R and MC4R will also move feeding, flushing and arousal, and a first-in-human room isn't a melanocyte dish. Dorr, Lines, Levine and colleagues put the peptide into a small human study, Life Sciences 1996, and wrote down what happened. Pigment rose. Nausea happened. Stretching and yawning happened. Spontaneous erection happened. Appetite moved. The group did not hide the extras. That honesty is why the later sexual-function programme had a paper trail instead of a rumour, and why a research catalogue can still name the pan-agonist as a probe rather than as a scandal. Industry later followed the arousal signal into PT-141. Palatin named the structure bremelanotide. The FDA licensed Vyleesi in 2019. The parent ring remains the unselective tool. Origin stories in this field are often tidier than the notebooks. This one was written down at the time.

In short. The first human study recorded a tan and also nausea, yawning, arousal and a quieter appetite. Those extras were written down, and later programmes followed some of them.

The melanocortin receptors are class-A, rhodopsin-like G-protein-coupled receptors: seven transmembrane helices, an extracellular face that binds peptide, an intracellular face that acts as a guanine-nucleotide exchange factor for a heterotrimeric G protein. There are five of them in mammals, numbered MC1R to MC5R in the order they were cloned, which is not the order of their physiological importance and is a standing irritation if you teach the family. Roger Cone, Kathleen Mountjoy and colleagues cloned MC1R from melanoma RNA in 1992 and then the rest of the family in short order. MC1R was the MSH receptor everyone already believed in. MC2R was the ACTH receptor the adrenal had been using since the 1950s. MC3R, MC4R and MC5R were the surprises: three more GPCRs with the same HFRW pocket, sitting in brain and in exocrine glands, waiting for someone to knock them out. The knockout mice did the teaching. Mc4r-null mice eat, grow and become obese. Mc1r-null mice are yellow because pheomelanin wins. Mc5r-null mice have a sebum defect. Mc3r-null mice have a subtler energy-balance phenotype. A family you can clone, knock out and occupy is a family a catalogue can name without inventing a job.

In short. Five related receptors were cloned in the 1990s. Knockout mice then showed pigment, appetite and oil as separate jobs of the same family.

Gs is the default G protein. Occupancy rearranges the helices. The cytoplasmic face catalyses GDP-to-GTP exchange on Gαs. Gαs-GTP finds adenylyl cyclase. Cyclase makes cyclic AMP from ATP. Protein kinase A reads the cyclic AMP, phosphorylates CREB and a list of other substrates, and the cell writes whatever programme that receptor, in that tissue, is for. In a melanocyte the programme is MITF, then tyrosinase, then eumelanin. In a paraventricular neuron the programme is a change in excitability and in peptide release that the organism experiences as satiety. In a sebocyte the programme is lipid synthesis for sebum. The second messenger is the same nucleotide. The invoice is not. Some of these receptors also recruit β-arrestin, and some of them couple in part to other G proteins in particular assays, and the biased-agonism literature exists. For a working map, Gs–cAMP is the sentence you write first. Lefkowitz and Kobilka's chemistry Nobel in 2012 was for this architecture in general, not for melanocortins in particular. The architecture is why a nanomolar peptide can move a micromolar messenger, which still feels slightly like cheating until you remember the enzymes in between.

In short. These receptors mostly raise cyclic AMP inside the cell. The same messenger means pigment in skin, fullness in brain, or oil in a gland, depending on the receptor.

Amplification is arithmetic, not a metaphor. One occupied receptor can load tens to hundreds of G proteins because the receptor is a catalyst, not a stoichiometric sponge. Each Gαs-GTP can occupy adenylyl cyclase long enough to make many cyclic AMP molecules. Each cyclic-AMP-activated protein kinase A can phosphorylate many substrates. A nanomolar occupancy in the pocket can therefore raise a micromolar messenger in the cytosol, which is the only magic in this family and is not magic. Local nanodomains — AKAPs, phosphodiesterases sitting next to the cyclase — mean a cyclic AMP rise next to a channel is not a cyclic AMP rise next to the nucleus. That's why two ligands at the same receptor can write different intracellular sentences if they prefer different nanodomains or different arrestin versus G-protein balances. Melanotan II and bremelanotide share a ring and don't write identical sentences. Desensitisation is the other half: G-protein-coupled receptor kinases phosphorylate the occupied receptor, β-arrestin binds, the receptor is pulled inward. More ligand is not more signal forever. A first-hour flush in a melanocortin study is often that machinery, not a reason to double the concentration.

In short. One receptor can make a cloud of cyclic AMP because enzymes sit in between. The cell then turns the receptor off, so more ligand is not more signal forever.

The peptide doesn't need to enter the cell. That sentence is the whole point of a plasma-membrane GPCR, and it is the sentence that still gets lost in the noise. Occupancy outside rearranges helices. Information crosses the bilayer as conformation. Cyclic AMP is made on the inner face. The heptapeptide, in the boring and correct case, is still outside, or is on its way to a lysosome after the receptor was internalised. KPV is the exception that proves the rule: a tripeptide that can also be cargo on PepT1, with intracellular NF-κB consequences that do not all require the tanning receptor. Melanotan II is not that exception. It is too large for PepT1, it is a GPCR ligand, and treating it as a cell-penetrating peptide is a category error. The lactam is a protease trick, not a bilayer ticket. If you can't say whether the ligand sat on a receptor or crossed as cargo, you haven't yet named the experiment. For this ring the lock is extracellular. Name the subtype. Then measure the nucleotide.

In short. Melanotan II works from outside the cell by changing the receptor's shape. It does not need to go inside. A much smaller fragment, KPV, can travel a different route.

MC1R on a melanocyte is the pigment receptor the public already thinks it knows. Occupancy, α-MSH or a synthetic agonist, raises cyclic AMP. Protein kinase A phosphorylates CREB. CREB, with other inputs, writes MITF, microphthalmia-associated transcription factor, the master transcription factor of the melanocyte. MITF writes TYR, tyrosinase, and TYRP1 and DCT (TYRP2), the enzymes that take tyrosine through DOPA and dopaquinone into the melanin polymers. When the cyclic AMP signal is strong, the polymer is eumelanin: brown-black, a broad ultraviolet absorber, photoprotective in the ordinary sense that a physical chemist would accept. When the cyclic AMP signal is weak, dopaquinone is diverted toward cysteine conjugates and the polymer is pheomelanin: red-yellow, a poorer absorber, and in some assays a source of reactive oxygen rather than a shield. The switch isn't a lifestyle. It is a receptor, a cyclic nucleotide, a transcription factor and a pair of polymer chemistries. A brochure that says 'melanin' as if there were one pigment hasn't looked at a melanosome. Melanotan II occupies this receptor with enthusiasm. That was the design. The other receptors weren't a surprise to the chemists; they were a surprise if you had only wanted a tan.

In short. MC1R tells pigment cells to make dark eumelanin. If the receptor is weak, they make red-yellow pheomelanin instead, which protects less well against ultraviolet light.

The red-hair-colour alleles are the cleanest genotype-to-phenotype story in human pigmentation. R151C, R160W and D294H are the common European hypomorphs: missense changes that leave a receptor on the surface but blunt the cyclic AMP response to α-MSH. Heterozygotes tan poorly. Compound heterozygotes and homozygotes are the classic red-hair, fair-skin, freckled, burns-rather-than-tans phenotype. Valverde, Rees, Sturm, Duffy, Palmer — the association papers of the 1990s and 2000s — mapped that colouring onto those alleles with a clarity most complex traits never get. The receptor is still a receptor. A hypomorph isn't a deletion. Residual signalling, ligand-independent constitutive activity, and the rest of the pigment genome still move the phenotype. But if you want a single-gene sentence about why some skin never browns, MC1R is that sentence. Arizona's photoprotection idea was aimed at that skin: raise eumelanin without ultraviolet, especially where the endogenous hormone is shouting at a deaf receptor. Whether a super-agonist can shout loudly enough at a hypomorph is an empirical question, subtype by subtype, allele by allele, and not a reason to write the research ring as a cosmetic.

In short. Common red-hair versions of MC1R answer poorly to the natural hormone. Fair skin, freckles and burning follow. That is one of the cleanest gene-to-colour stories we have.

Melanoma statistics travel with that colouring, and the travel isn't only 'these people burn, therefore they get more ultraviolet, therefore they get more melanoma'. They do burn. Cumulative ultraviolet is a first-class cause. There is also a pheomelanin-intrinsic story: Mitra, Fisher and colleagues, in a mouse with a red-hair Mc1r allele, showed oxidative DNA damage and melanoma risk that did not require ultraviolet, which is a disturbing paper if you had hoped pigment chemistry was only a filter. Human epidemiology is messier than a genetically red mouse. MC1R variants raise melanoma risk in fair-skinned cohorts after you adjust, imperfectly, for sun exposure and for naevus count. The practical sentence for a Melanotan II page is simpler than the oncology: a hypomorphic MC1R tilts the polymer toward pheomelanin, tilts the skin toward burning, and travels with melanoma risk. Afamelanotide was built, in part, as a photoprotective agonist for skin that tans poorly. Erythropoietic protoporphyria, the licensed indication, is a different phototoxicity — ferrochelatase deficiency, protoporphyrin in the skin, pain in visible light — but the receptor is the same MC1R, and eumelanin is still the pigment you are trying to write. That implant is Melanotan I, not this ring.

In short. Red-hair MC1R variants travel with higher melanoma risk. Some of that is burning. Some of it may be the red pigment itself making oxidative damage.

MC2R is the ACTH receptor. It lives on zona fasciculata cells of the adrenal cortex. Occupancy raises cyclic AMP, protein kinase A phosphorylates the machinery that moves cholesterol to CYP11A1, and cortisol is written. The receptor is fussy. It wants ACTH, not α-MSH, and it needs melanocortin-2 receptor accessory protein, MRAP, to traffic and to signal. Familial glucocorticoid deficiency type 1 is MC2R loss-of-function; type 2 is MRAP. Melanotan II, for all its promiscuity at MC1, MC3, MC4 and MC5, is a poor MC2R agonist, which is why a pan-melanocortin probe doesn't routinely present as an ACTH analogue. That sentence belongs early, because 'melanocortin' on a protocol line is easy to over-read as the whole family including the adrenal. ACTH is a melanocortin. It isn't the melanocortin this ring is holding. The corticotroph, the adrenal, the circadian cortisol curve — those are a different page, a different axis, a different ligand. Name MC2R so you can leave it. Then return to the four receptors the lactam actually occupies, which are already enough to fill a first-in-human room with pigment, nausea, appetite change and arousal without borrowing the adrenal.

In short. MC2R is the adrenal ACTH receptor and needs a helper protein. Melanotan II barely touches it, which is why a tanning probe is not a cortisol drug.

MC3R is the quieter of the two central receptors and isn't a footnote. It sits on POMC neurons themselves, among other sites, and functions in part as an inhibitory autocrine brake: α-MSH released from the neuron can occupy MC3R on the same population and temper the output. Knockout mice have a metabolic phenotype that is not identical to MC4R knockout — more of a shift in body composition and feed efficiency than the frank hyperphagia of MC4R loss. Human MC3R variants exist and are argued over; they haven't given us a licensed agonist of their own. Melanotan II occupies MC3R because Melanotan II occupies almost everything in the family. That's a feature of a pan-agonist and a nuisance if you wanted to know which receptor moved feeding. Bremelanotide leans toward MC3 and MC4, which is why the sexual-function literature sits on those two and not on the melanocyte. Energy balance is a circuit. MC3R is one node. MC4R is the node the clinic actually met. The extras were never off-target in the medicinal-chemistry sense of hitting a different protein family. They were on-family, on-purpose promiscuity, which is a cleaner sentence once you've named both receptors.

In short. MC3R helps the brain's energy circuit and partly brakes the cells that make α-MSH. It is real. MC4R is the one obesity genetics made famous.

MC4R is the hypothalamic receptor that made this family a metabolic subject. It is expressed on paraventricular neurons, on brainstem neurons that run autonomic outflow, and in a list of other nuclei a neuroanatomist can recite. Occupancy by α-MSH is an appetite brake and a push on energy expenditure. Occupancy by AgRP is the opposite: AgRP is an inverse agonist, not merely a blocker, because MC4R has constitutive activity and AgRP turns that down. Yeo, Farooqi, O'Rahilly and colleagues at Cambridge showed, in the late 1990s and then in a New England Journal paper in 2003, that heterozygous loss-of-function mutations in MC4R are the most common single-gene cause of severe obesity in the cohorts that bother to sequence it. A few percent of severe early-onset obesity. Dominant with incomplete penetrance. Hyperphagia from childhood, increased lean mass, accelerated linear growth — a phenotype that isn't 'they eat too much' as a moral sentence. The neuron is an appetite brake. Break the receptor and the brake fails. That's a first-class melanocortin output. A tanning page that leaves it out hasn't described the family, and a pan-agonist page that leaves it out hasn't described why appetite moved in Arizona.

In short. MC4R in the hypothalamus is an appetite brake. Inherited damage to one copy is the most common single-gene cause of severe obesity.

The 2003 paper is the document, not a tweet. Farooqi, Keogh, Yeo, Lank, Cheetham, O'Rahilly: Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene, New England Journal of Medicine, 348: 1085–1095. They sequenced MC4R in people with severe obesity, found a spectrum of heterozygous mutations, showed that the mutations that wrecked receptor function in a dish tracked with the clinical severity, and put a tanning-hormone receptor in the endocrine clinic. Subsequent work filled in the signalling: Gs, cyclic AMP, but also a β-arrestin and MAPK conversation that some obesity mutations hit more than others, which is why not every missense is the same disease. Rare homozygous or compound-heterozygous complete loss is more severe. The common heterozygous loss-of-function is already enough to be the leading monogenic obesity. Polygenic obesity is still most of obesity. MC4R isn't 'the' obesity gene. It is the most common of the rare, severe, early ones, and it is a melanocortin receptor, which is the only reason it belongs in a page about a tanning analogue. When Hadley's volunteers ate less, they were occupying this receptor, among others. That was never an accident of formulation.

In short. Farooqi and O'Rahilly sequenced MC4R in severe obesity and showed the broken receptors matched the broken appetite. That paper moved this family into the clinic.

POMC deficiency is the rarer, cleaner experiment of nature. If you cannot make the ligand, MC4R never sees α-MSH, MC1R never sees it either, and ACTH is missing so the adrenal never sees that. The child is ACTH-deficient, obese, and often red-haired, because the pigment receptor and the appetite receptor lost the same peptide. PCSK1 deficiency wrecks the convertase that cuts POMC and proinsulin and a list of other prohormones; obesity is part of a broader endocrine mess. Leptin-receptor deficiency wrecks the upstream signal that tells POMC neurons to fire. Three genetic lesions, one pathway, one licensed peptide that was built to occupy MC4R anyway. Setmelanotide, RM-493, Imcivree, Rhythm Pharmaceuticals: a cyclic octapeptide MC4R agonist. Kühnen, Krude and colleagues treated POMC-deficient patients and published the weight loss in the New England Journal in 2016. The FDA licensed it in 2020 for chronic weight management in people six and older with POMC, PCSK1 or LEPR deficiency, later adding Bardet-Biedl syndrome. When a tanning-hormone family has an FDA-approved obesity drug, the family left the booth. Setmelanotide is that drug. Melanotan II is not. Same ancestral family, different selectivity, different legal class.

In short. If the body cannot make α-MSH, you get obesity, cortisol failure and often red hair together. Setmelanotide is the licensed MC4R agonist for those rare pathway diseases.

Leptin is the upstream signal that made the arcuate melanocortin circuit a textbook. Friedman cloned leptin from the ob mouse; the receptor lives on POMC neurons and on AgRP neurons. Leptin rising, as the warehouse fills, excites POMC cells so they release α-MSH onto MC4R, and silences AgRP cells so the inverse agonist withdraws. Starvation is the opposite: POMC quiet, AgRP loud, appetite up. That's why leptin-receptor deficiency looks like POMC deficiency looks like MC4R deficiency, one floor down each time, and why setmelanotide can bypass a broken leptin receptor or a missing ligand and still occupy the last receptor. MRAP2, a relative of the adrenal accessory protein, helps MC4R traffic and signal; some rare obesity mutations hit MRAP2 instead of the receptor itself. The circuit is allowed to have more than one named protein. A pan-agonist given to a volunteer still occupies MC4R on this circuit, which is why appetite moved in Arizona. It also occupies MC1R, MC3R and MC5R, which is why appetite was never the only thing that moved. Selectivity is which protein you occupy. A pan-agonist is a tool that refuses that choice on purpose.

In short. Leptin talks to brain cells that release α-MSH onto the appetite receptor. Break leptin, the hormone, or MC4R, and the same brake fails. Setmelanotide occupies the last step.

MC5R is the sebum receptor. It is expressed on sebaceous glands and on other exocrine epithelia. Knockout mice have a defect in water repulsion and thermoregulation that traces to altered sebum, which makes sense once you remember that fur is a hydrophobic coat a gland has to oil. Human sebocytes express MC5R; α-MSH can change their lipid programme in culture. This is a first-class melanocortin output that people still treat as a footnote because it doesn't photograph as a tan. A pan-agonist will occupy MC5R because that's what pan means. Whether a given flushing or a given change in skin oil in an old Arizona volunteer study was MC5R, MC1R, autonomic, or all three isn't a question a comment thread gets to answer. Five receptors were cloned because five receptors exist. Constitutive activity is the other fact this family teaches well. MC4R signals somewhat without ligand; AgRP is an inverse agonist that turns that basal signal down. ASIP does the equivalent at MC1R. Melanotan II is a heavy on. Inverse agonism is why 'blocker' is a sloppy word here, and why you have to say agonist, antagonist or inverse agonist on purpose, even when the sentence feels fussy.

In short. MC5R sits on oil glands. The family does sebum as well as pigment and appetite. A pan-agonist will touch that receptor too. Some of these receptors are partly on even without hormone.

Mac Hadley and Victor Hruby, University of Arizona, spent the 1980s and 1990s making melanocortin analogues that would raise eumelanin without ultraviolet. Fair MC1R-variant skin tans poorly and burns well; a peptide that occupied MC1R and wrote eumelanin was, on paper, photoprotection you could dose. The linear analogue stayed closer to α-MSH and became Melanotan I. The cyclic analogue became Melanotan II. Photoprotection was the brief. The receptor sheet was larger than the brief. That isn't a scandal. It is what happens when you occupy a family of GPCRs that share a pocket and do not share a tissue. The programme is sometimes written as if the extras were discovered by accident in a sunbed. They were discovered in a physiology laboratory that was already measuring behaviour as well as pigment, because Hadley was a comparative physiologist and stretching, yawning and grooming were already in the α-MSH literature. A cyclic super-agonist made those readouts louder. The tanning story is the public story. The notebooks already had the rest of the family in them. A research page owes both halves, and that's a nicer origin than a rumour.

In short. Arizona wanted a peptide that would darken pigment without sun. The same peptide also talks to brain and gland receptors, which the notebooks already knew how to measure.

Dorr, Lines, Levine and colleagues, Life Sciences 1996, is the human document a paper actually has to cite. A pilot phase-I study of a superpotent cyclic melanotropic peptide. Small numbers, as pilots are. Pigment rose, which was the intended MC1R readout. Nausea happened, which is brainstem melanocortin tone, MC4R neighbourhoods that run aversive and emetic circuitry, area postrema and related nuclei. Stretching and yawning happened, old in the α-MSH literature, easy to joke about, still a real central readout. Spontaneous erection happened in men. Appetite moved. Faces flushed. A pan-agonist in a volunteer is a pan-agonist. The group wrote the extras down instead of editing them out, which is why a later sexual-function programme could point at a paper rather than at a rumour. Industry followed the arousal signal. Palatin took a close analogue through to a label. The parent ring was not that programme's finished medicine. It was the existence proof that central melanocortin tone is ligand-gated in humans, at doses that also tan. Existence proofs are how fields start. They are not how medicines finish.

In short. The 1996 human study is small and honest: pigment plus nausea, yawning, arousal and appetite change. Later drug programmes followed some of those signals and left the rest.

Those extras map onto receptors if you let them. Pigment is MC1R on melanocytes. Appetite is MC3R and MC4R in hypothalamus. Flushing is vascular and autonomic, a mixture a first-hour study isn't designed to dissect. Arousal — stretching, yawning, spontaneous erection in men — is central melanocortin tone, MC4R heavily implicated, with a spinal and autonomic half that the sexual-function papers spent the next two decades on. None of that was off-target in the sense of hitting a different protein family. It was on-family, on-purpose promiscuity. A pan-agonist is a tool for asking whether a phenotype is melanocortin-gated at all. It is a poor tool for asking which subtype did the work. If you want subtype, you change the molecule, or you use a knockout, or you use an antagonist, or you pick the licensed cousin that was taken through to a label on one job. Melanotan II remains the research pan-agonist because that's the question it answers. Subtle is a different vial. KPV is the design move in the other direction. Bremelanotide is the design move that kept the ring and changed the terminus.

In short. The extra effects were the other melanocortin receptors doing their jobs. A pan-agonist is how you ask whether the family is involved, not which member did it.

Nausea is the melanocortin extra a first-hour study should expect and a paper should name. MC4R sits in the brainstem as well as in the paraventricular hypothalamus, including neighbourhoods that run aversive and emetic tone. Area postrema and related nuclei are how a peptide that never needed to be a gut hormone can still make a volunteer reach for a basin. Afamelanotide, bremelanotide and setmelanotide all carry gastrointestinal events on their labels; Melanotan II did in Arizona. That's on-family pharmacology, not a contaminant in the cake. Stretching and yawning are the other brainstem signature. A feeding study that doesn't watch for malaise will count nausea as satiety and publish a cleaner curve than the animal lived. A human study that doesn't list nausea has probably not given a melanocortin agonist, or has not asked. The extras are data. Write them down, as Dorr did, and then decide whether your question can survive them. A pigment assay in a dish doesn't have a brainstem. A rodent feeding assay does. Choose the assay that matches the claim, and don't file malaise under efficacy.

In short. Melanocortin agonists often cause nausea because appetite receptors also sit in brainstem areas that trigger queasiness. That is the family, not a dirty sample.

Afamelanotide is the linear analogue that finished as a medicine. [Nle4, D-Phe7]α-MSH, Melanotan I, then Scenesse, Clinuvel. An implant, not a cyclic heptapeptide in a vial. The EMA licensed it for erythropoietic protoporphyria in 2014; the FDA followed in 2019. EPP is ferrochelatase deficiency, protoporphyrin IX in erythrocytes and skin, burning pain in visible light rather than a delayed ultraviolet burn. Eumelanin in the epidermis is a filter for that light. The implant is a licensed photoprotective melanocortin agonist in a defined disease, MC1R-forward, with a pharmacovigilance file and a regulated device. It is Melanotan I, not Melanotan II. Different molecule, different label, different legal class. The research pan-agonist on a catalogue is the cyclic cousin, and the cyclic cousin is a different experiment. Photoprotection as a research idea is allowed on this page because that is why Arizona built both analogues. Photoprotection as a product claim for the cyclic ring is not allowed, because no regulator has given that ring that job, and because a pan-agonist is a poor photoprotection tool once you have a linear analogue that stays closer to pigment.

In short. The linear cousin, afamelanotide, became a licensed implant for a rare light-pain disease. Melanotan II is the cyclic parent, a different molecule with a different legal class.

Take the Melanotan II ring and leave the C-terminus as a carboxylic acid instead of an amide, and the literature shifts. Less MC1, more MC3 and MC4. Pigment recedes as the question; central melanocortin circuitry becomes the question. Palatin named the structure bremelanotide. The research code that stuck is PT-141. The chemistry is still a cyclic heptapeptide with norleucine, D-phenylalanine and the Asp-Lys lactam. The C-terminal amide-to-acid change is a small edit with a large effect on which receptor the ring prefers, which is a useful lesson in how little sequence it takes to change a family portrait. Early development chased male erectile function and then moved, for regulatory and clinical reasons, to acquired, generalised hypoactive sexual desire disorder in premenopausal women. The FDA licensed Vyleesi in 2019 as an on-demand subcutaneous injection. Nausea is common. That's the medicine, in its indication, with its pharmacovigilance and its device. A research vial of the named heptapeptide is a laboratory ligand. Patriot Peptides is not Palatin. The two objects share a backbone idea. They don't share a legal class.

In short. PT-141 is Melanotan II's ring with the end left as an acid. It prefers the brain receptors over pigment, and bremelanotide became a licensed desire medicine in 2019.

Amide versus acid is a medicinal-chemistry sentence worth slowing down for, because the rest of the ring is identical and the phenotype is not. A C-terminal amide is the native finish of α-MSH and of Melanotan II; amidation is a PAM enzyme's job in the secretory pathway, and chemists put it on the resin as an amide resin or as a post-cleavage conversion. A free carboxylic acid is one oxygen different and a charge different at physiological pH. Receptor pockets notice charge. MC1R notices it enough that pigment recedes as the dominant question. MC3R and MC4R still bind the ring. That's ligand-dependent receptor choice, the adult version of 'it does not tan as much'. It isn't a Kenakin bias table anyone should fabricate for a catalogue page, and it isn't identity. Treating Melanotan II and PT-141 as interchangeable because they share a lactam is how you fail the oral exam this page is quietly setting. Same family, different terminus, different preferred locks, different literature, different legal object when Palatin's medicine is in the room. Write the C-terminus on the protocol line. Then write which receptor you actually meant.

In short. Changing the last chemical group from an amide to an acid shifts the ring away from pigment receptors and toward the brain ones. That small edit is why PT-141 is not Melanotan II.

Setmelanotide is the third licensed cousin and the one a metabolic bench has to name. A cyclic octapeptide, MC4R-forward, Rhythm Pharmaceuticals, Imcivree, FDA 2020, later Bardet-Biedl as well as POMC, PCSK1 and leptin-receptor deficiency. Kühnen and Krude's New England Journal paper in 2016 is the POMC-deficiency treatment document. The drug occupies the receptor the missing ligand never reached. It isn't Melanotan II with a better press officer. Selectivity, indication, device, pharmacovigilance, a named genetic population: those are how a melanocortin agonist becomes a medicine rather than a probe. The pan-agonist remains useful on a bench that wants to know whether a phenotype is melanocortin-gated at all, before anyone spends a year on a subtype-selective analogue. Pigment in melanocytes, cyclic AMP in MC4R-expressing neurons, feeding suppression in rodents: those are fair assays. They are why the pan-agonist stays in a research catalogue. They aren't Imcivree, and they aren't a diet. Rare genetic obesity on this pathway is a clinic and a sequencing panel. A lyophilised cyclic heptapeptide is a laboratory ligand. Reading them on the same afternoon is encouraged. Stapling them into a protocol isn't.

In short. Setmelanotide is a licensed MC4R medicine for rare genetic obesity. Melanotan II occupies that receptor among others, as a research probe, not as that drug.

The licensed cousins, taken together, are the proof of the family. Afamelanotide occupies MC1R for photoprotection in EPP. Bremelanotide occupies MC3R and MC4R for a defined desire indication. Setmelanotide occupies MC4R for rare genetic obesity on the POMC pathway. Three peptides, three jobs, three labels, three companies, three decades of chemistry that started as a tanning analogue on a Tucson bench. That's success as a pharmacologist means it: the ancestral ligand was real, the receptors were clonable, the analogues were makeable, and at least three of the phenotypes were large enough and clean enough to survive a regulator. Melanotan II is none of those three medicines. It is the unselective parent those programmes learned from, still the right probe when a bench wants to know whether a melanocortin phenotype is ligand-gated at all. The success of the family isn't a licence to treat the parent as a sunbed, a desire injection, or a weight medicine. The success of the family is the reason the parent is still interesting as chemistry. Match the ligand to the question. Leave the labels on the medicines that earned them.

In short. Three licensed drugs came out of this family: a light-pain implant, a desire injection, a rare-obesity agonist. Melanotan II is the unselective research parent, not those medicines.

Subtract α-MSH until three residues remain: lysine-proline-valine, the C-terminal tail, often itself amidated in the reagents people actually weigh. The HFRW core is gone. Most of the MC1R tanning potency is gone. Most of the MC4R appetite agonism is gone. What remains, in the papers that measured it, is an anti-inflammatory fragment. Luger's group, in keratinocytes and in skin inflammation models, showed that α-MSH and C-terminal fragments still calm inflammatory transcription. Getting's group, in macrophages and in rodent inflammation, showed melanocortin peptides reducing leukocyte recruitment and cytokine output, and spent time on which receptor, if any, the smaller fragments still needed. The master switch those assays keep reading is NF-κB: the transcription factor that puts TNF, IL-6, IL-1β and a list of adhesion molecules on the page. KPV reduces NF-κB reporter activity, preserves IκB, and reduces p65 nuclear translocation in keratinocytes and in macrophages. That's a small, precise, interesting reagent. It is a weak pigment signal, which is the point of the subtraction, not a failure of it. A pan-agonist in a colitis model will occupy four receptors and give you a phenotype you can no longer assign.

In short. KPV is the last three amino acids of the natural hormone, kept because they still calm inflammatory genes after the tanning piece is removed.

Dalmasso, Charrier-Hisamuddin, Nguyen, Yan, Sitaraman and Merlin, Gastroenterology 2008: PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. PepT1 is SLC15A1, a proton-coupled oligopeptide transporter on the apical membrane of small-intestinal enterocytes, built to absorb dipeptides and tripeptides from digested protein. Inflammation induces it, including in colon, which isn't its quiet-state address. A tripeptide that is a PepT1 substrate can therefore enter epithelium by a nutrient transporter, not only by a melanocortin receptor. Melanotan II doesn't fit that hole. Thirteen-residue α-MSH doesn't. The transporter is why the fragment and the pan-agonist aren't interchangeable even before you look at receptor pharmacology. A colitis paper that can't name PepT1 hasn't yet explained how an oral tripeptide would get in. A melanocyte paper doesn't need PepT1; it needs MC1R, cyclic AMP, MITF and a melanin pellet. Two ligands, two questions, one ancestral hormone. The shared design sentence is what you kept and what you threw away. Everything else — transporter versus receptor, colon versus melanocyte, NF-κB versus tyrosinase — is the experiment you actually ran.

In short. Gut cells have a transporter that swallows very short peptides. KPV can ride it. Melanotan II is too large, and is a receptor ligand rather than a cargo.

If KPV still worked only through MC1R, there would be little reason to isolate it. You'd use α-MSH, or afamelanotide, or Melanotan II, and you'd accept the pigment. Several groups have shown residual anti-inflammatory activity in MC1R-null cells, in antagonist-blocked systems, or at concentrations and in tissues where a tanning assay would have been silent. The molecular identity of every remaining target isn't a solved crystal structure. Intracellular uptake via PepT1, subsequent IκB effects that don't require a GPCR at the plasma membrane, and residual activity at other melanocortin receptors have all been proposed. Dependence on MC1R is incomplete. That incompleteness is the design. It's why a lab that wanted NF-κB in epithelium without MITF in melanocytes reaches for the tripeptide. It's why a lab that wanted eumelanin reaches for a full agonist and leaves KPV in the freezer. Subtype-selective tools and receptor-null systems are how you find out which remaining target did the work in your assay. The catalogue can't do that experiment for you. It can put both sequences on the shelf with masses attached.

In short. KPV still calms inflammation in some systems that lack the tanning receptor. That leftover activity is why the fragment exists as its own reagent, opposite to the pan-agonist.

Cyclic AMP, in a cell line that actually expresses the subtype you named, is occupancy as a nucleotide: ELISA, HTRF, a GloSensor, the old radioimmunoassay. Pigment, in melanocytes or in a melanoma line, is MITF and tyrosinase and a melanin pellet you can see. Feeding, in a rodent, is grams over hours after a central or peripheral dose, with the usual caveat that nausea looks like satiety if you aren't watching. NF-κB, for the fragment, is a reporter, a p65 immunofluorescence, an IκB blot, a cytokine ELISA. Those four readouts aren't interchangeable. A cyclic AMP rise in an MC1R line isn't a quieter DSS colon. A feeding suppression isn't a tan. Writing 'melanocortin activity' without naming the assay hasn't yet done the experiment. Concentration matters: nanomolar at a GPCR, micromolar if you're asking a transporter to carry a tripeptide, and a rumour dose isn't a Kd. Spare receptors mean EC50 can sit below Kd. Species matters: rodent MC3R and human MC3R aren't a copy-paste. Write the assay. Then write the ligand. Then write the subtype, or admit you used a pan-agonist on purpose. That's the adult version of picking a tool.

In short. Cyclic AMP, pigment, feeding and inflammatory-gene readouts are four different measurements. A melanocortin paper has to name which one it ran, and at which receptor.

Cell-type choice is a control, not a convenience. A HEK293 well transfected with MC1R will tell you whether the ring raises cyclic AMP at that subtype. It will not tell you what a melanocyte does with MITF, and it will not tell you what a paraventricular neuron does with firing rate. Primary melanocytes, a decent melanoma line with endogenous MC1R, hypothalamic explants or a feeding assay, sebocytes if you are in the MC5R neighbourhood: those are the tissues the family actually uses. Knockouts and antagonists are how you assign the subtype after a pan-agonist has told you the family is involved. An MC4R antagonist that spares the pigment readout is information. An Mc1r-null melanocyte that still sees a cyclic AMP bump is a contamination or a second receptor. Species is a variable twice: the receptor sequence, and the downstream transcription. A yellow mouse is an Mc1r genetics lesson, not a human red-hair protocol. If this sounds like a lot of work, that's because a cyclic heptapeptide with four Gs-coupled addresses is a lot of work. A single pigment photograph is allowed as a scout. It isn't allowed as the only figure in a family-wide title.

In short. Pick the cell that has the job you are claiming. A kidney-cell line with one receptor added is not a pigment cell, and it is not a hunger neuron.

Identity is a chromatogram and a mass, not a nickname. Melanotan II is a cyclic heptapeptide, about 1024 daltons, a lactam that a linear deletion peptide will not copy, a different peak from KPV at 342 daltons and from the free-acid cousin at about 1025. HPLC area-percent without mass spectrometry can still be a clean peak of the wrong chain. A missed coupling in solid-phase synthesis makes an N-minus-one contaminant that looks almost right on a cheap ultraviolet scan. Asp-Lys lactamisation can fail and leave a linear peptide with the same residues and a different pharmacology. D-phenylalanine can be the L-amino acid if the building block was mislabelled, and potency will collapse. That's why the interesting number isn't 'did we make a peptide' but 'what else is in the peak', and why a certificate that names sequence, mass and purity is the invoice a research ligand owes you. Nicknames rotate every season. The sequence does not care. Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 is Melanotan II. If the peak isn't that mass, you're holding a different experiment, and that's useful to know before the first well is seeded.

In short. Melanotan II is a named chain with a named mass. A clean HPLC peak still needs a mass to prove it is the right peptide, including the ring and the D-amino acid.

Pharmacological controls are how you name the lock. An MC4R antagonist in a feeding study, an MC1R antagonist or an Mc1r-null melanocyte in a pigment study, a cyclic AMP assay in a line that expresses one subtype: those are the tools. AgRP as an inverse agonist at MC4R is a different tool again, because it turns basal activity down rather than merely keeping α-MSH off. ASIP at MC1R is the pigment equivalent. A pan-agonist plus no antagonist is a family-level result, which is allowed if the claim is family-level. A pan-agonist plus a waist measurement and a tan photograph is two family-level results stapled together, which is a poster, not a paper. Desensitisation is a time-course variable: GRKs and β-arrestin will pull the receptor in, and a twenty-four-hour treatment isn't a five-minute cyclic AMP bump. Washout, restimulation, an arrestin recruitment assay if you're going to mention bias: those are the moves. Melanotan II and bremelanotide share a ring and don't write identical intracellular sentences. If you claim they do, show the nucleotide, the arrestin, and the tissue. That's how a pan-agonist stays a tool rather than a blur.

In short. Use blockers or receptor-missing cells so you can tell which lock did the work. A pan-agonist without those controls only tells you the family was involved.

We're not going to write a reconstitution schedule, a stacking plan, or a sunbed protocol. Those are papers, indications, or wishes, and they aren't the job. The papers that already ran melanocyte cyclic AMP assays, knockout feeding studies and first-in-human Arizona rooms are in PubMed, with concentrations and exclusion criteria. Go there if you're running an experiment. Stay here if you wanted the ring explained: sequence, lactam, four receptors, three licensed cousins, a tripeptide pointing the other way, and a pair of research sequences with masses. Dosing, stacking the tail with the pan-agonist, and filing a lyophilised cake under photoprotection or desire are category errors we won't make. A Phase 1 Arizona paper from 1996 is a paper. A 2019 or 2020 FDA label is a label. A lyophilised cake with a sequence on the certificate is a cake. Reading them on the same afternoon is encouraged. Stapling them into a protocol isn't. The physiology doesn't change because someone wanted a shorter path between a receptor and a person. The ring is still a probe of four Gs-coupled addresses.

In short. This is the biology of the ring, not instructions for using it. The papers already contain the methods. The medicines already have labels. The cake is a named laboratory sequence.

The listing is lyophilised Melanotan II, ten milligrams, ≥98 percent by HPLC, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, molecular weight about 1024, CAS 121062-08-6. A white to off-white cake in a vial, a certificate of analysis, a reconstitution kit. It is the same carbon skeleton the Arizona papers named. It is a laboratory reagent. The form is the form you weigh into a cyclic AMP assay, a melanocyte pigment assay, a transfected-subtype screen, a rodent feeding study whose malaise you actually watch. Purity is a chromatogram, not a feeling. Water, light and freeze–thaw are the enemies of a peptide in solution; the lyophilised solid is how you store it. None of those sentences is a dose. None of them is a route. None of them is a schedule. A protocol that can't say how many nanomoles went into a well hasn't yet started. A social post that treats ten milligrams as a human serving hasn't read the label, and the label is the legal class of the object. The ring is a probe of four Gs-coupled addresses. It isn't a tanning medicine, and it doesn't become one by being weighed carefully.

In short. The vial is freeze-dried Melanotan II, ten milligrams, purity on a chromatogram, for weighing into experiments. That is a laboratory chemical, not a dose for a person.

Two related sequences sit nearby on the same family map, and the map has to stay a map. PT-141 is the free-acid analogue, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, about 1025 daltons, MC3/MC4-preferring, the named heptapeptide Palatin took toward a label as bremelanotide. Where the catalogue lists that ring, it is the laboratory ligand, not Vyleesi. KPV is Lys-Pro-Val, the C-terminal tripeptide, the NF-κB fragment, the PepT1 substrate, the design move that threw the HFRW core away. Three ligands, one family, three questions. A bench that opens the pan-agonist and hopes for a clean IκB readout hasn't matched the ligand to the question. A bench that opens the tripeptide and hopes for a tan hasn't read the subtraction. A bench that opens the free acid and writes a pigment title hasn't read the terminus. Neighbourhood, here, is a courtesy on a reading list. It isn't a combination claim. We'll sell you the named objects. We won't design the blot, and we won't write a protocol that pretends a cyclic pan-agonist is a tripeptide or a weekly desire injection. That's the unmix, and it's a kindness to the chemistry.

In short. PT-141 is the free-acid cousin pointed at brain receptors. KPV is the anti-inflammatory tail. Three named chains, three questions, not a mixed protocol.

Licensed neighbours are how you keep the legal classes honest. Afamelanotide is Scenesse, an implant, EPP, Clinuvel, MC1R-forward photoprotection. Bremelanotide is Vyleesi, an on-demand injection, HSDD, Palatin, MC3/MC4-forward. Setmelanotide is Imcivree, a daily injection, POMC/PCSK1/LEPR deficiency and later Bardet-Biedl, Rhythm, MC4R-forward. Those are medicines, in indications, with regulators attached. The research sequence is a laboratory ligand with a mass and a chromatogram. Patriot Peptides synthesises named structures and puts the papers next to the vials. We are not Clinuvel, not Palatin, not Rhythm, and not a tanning shop. A first-in-human Arizona paper is a paper. An FDA label is a label. A lyophilised cake is a cake. Adults can want both a paper and an appointment. Bundling them is how a research reagent becomes a medical claim it isn't allowed to be, and how a clinic becomes a webshop it is not. This paragraph is the unmix. The physiology above doesn't depend on it. The label does. The receptors will still be Gs-coupled in the morning, whether or not anyone opened a vial.

In short. Three medicines already came from this receptor family, each for one job. The research peptide is the named laboratory sequence, not those products and not a sunbed.

What a melanocyte, a paraventricular neuron, a sebocyte and a macrophage share is a GPCR architecture and an ancestral ligand. What they don't share is a phenotype. Cyclic AMP is the common coin. MITF, satiety, sebum and IκB are the jobs. The HFRW core spends that coin at four receptors with enthusiasm. The KPV tail spends almost none of it on pigment and still shows up in the inflammatory transcription assays. Farooqi and O'Rahilly spent the coin at MC4R and found childhood obesity. Hadley and Hruby spent it across the sheet and found pigment plus the extras a pan-agonist owes you. Palatin spent a close analogue at MC3 and MC4 and found a desire label. Rhythm spent a different cyclic peptide at MC4R and found a rare-obesity label. Clinuvel spent the linear analogue at MC1R and found a light-pain implant. The family is large enough for all of those papers. It isn't large enough to excuse using the wrong ligand. Match the receptor to the tissue. Match the ligand to the receptor. Then run the assay you actually designed. The pan-agonist is how you ask the family question. It is a poor way to skip the subtype question.

In short. Same messenger, different jobs in different cells. Use the pan-agonist for the whole family, and the licensed drugs only as the papers and labels describe them.

The parent is unselective on purpose, which is why a tanning study became a sexual-function study and why a laboratory should pick the receptor they actually mean before they pick the vial. Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 occupies MC1R, MC3R, MC4R and MC5R, Gs–cAMP throughout, negligible at MC2R. MC1R on melanocytes drives MITF, tyrosinase, TYRP1/2 and eumelanin. MC4R in paraventricular hypothalamus governs satiety; loss-of-function is a monogenic obesity syndrome, Farooqi and O'Rahilly, and setmelanotide is the licensed MC4R agonist for those rare diseases. Bremelanotide is an analogue developed as an on-demand MC3/MC4-forward agent; the FDA licensed Vyleesi in 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Afamelanotide, the linear cousin, is Scenesse for erythropoietic protoporphyria. KPV is the opposite design: the last three amino acids of α-MSH, kept for NF-κB. Those sentences are the molecular field this page was asked to keep, written out at the length they need. A pan-agonist is a beautiful probe of the whole family. Subtle is a different sequence, and that's a compliment to both.

In short. This ring occupies four receptors on purpose. That is why early volunteers got more than a tan, and why later medicines each picked one receptor-dominant job.

The neighbouring pages are the rest of the map. Melanocortins, from tanning receptors to inflammatory off-switches: the family portrait, POMC, five receptors, the pan-agonist and the tail on one page. Melanocortin circuits, pigment, appetite and PT-141: the free-acid cousin at the length that ring deserves, amide versus acid, why desire literature is not a tan literature. KPV, the anti-inflammatory tripeptide: Luger, Getting, Dalmasso, PepT1, IκB. How peptides talk to cells: occupancy, amplification, arrestin, the class-A physics this family sits on. Pathophysiology as a stack: receptor, cell, tissue, organism, so a tanning analogue that also cuts appetite is no longer a surprise. Read those if you're holding a different vial, or if you wanted the family rather than this ring. Stay here if you wanted to know why the lactam exists, why Dorr wrote the extras down, and why three licensed cousins don't make the parent a medicine. The figure is pigment and a receptor family. The readout is late. The pocket is early. The unselective occupancy was the point, and it still is.

In short. Other essays cover the whole family, the free-acid cousin, and the anti-inflammatory tail. This one is the Arizona pan-agonist, at the length the ring deserves.

Research-use-only. Not for human consumption / not a medicine. The lyophilised Melanotan II on this listing is a laboratory reagent, HPLC-characterised at ≥98 percent, labelled for in-vitro and preclinical work: a cyclic AMP assay, a melanocyte pigment readout, a transfected-subtype screen, a rodent feeding study whose malaise you actually record. The physiology in the paragraphs above is public, cited, and older than the vial. Use it to design the experiment you have the controls for, with the subtype named, the assay named, and the C-terminus written down so nobody confuses the amide with the acid. Read Hadley, read Dorr, read Farooqi, read the Vyleesi and Imcivree labels as labels, then weigh the cake. We'll sell you the cyclic heptapeptide. We won't tell you it is a tanning medicine, a desire injection, or a weight drug. Those jobs, where they exist, belong to other molecules with other regulators. This rate you can measure, in a tube, with a chromatogram on the bench beside it. The receptors will still be Gs-coupled in the morning.

In short. The vial is a research chemical for experiments, not a medicine and not a sunbed. The biology is public. Weigh it, name the receptor, and keep the claim the size of the chromatogram.